SCHEMBL6137280

SCHEMBL6137280

CCCCC(O)C#CCCCCCCCCCCCCC(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 4/20 0.73
PTPN7 P35236 5/20 0.66
TDP1 Q9NUW8 3/20 0.56
RECQL P46063 2/20 0.56
FFAR4 Q5NUL3 1/20 0.54
FFAR1 O14842 1/20 0.54
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
USP2 O75604 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
ALOX12 P18054 1/20 0.53
BLM P54132 1/20 0.53
KMT2A Q03164 1/20 0.53
MCL1 Q07820 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
EPHX2 P34913 1/20 0.53
GPR84 Q9NQS5 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137651 1.00 HMGCR (0.73) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL6137269 1.00 HMGCR (0.73) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL6137520 1.00 HMGCR (0.73) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL6137529 1.00 HMGCR (0.73) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL6137647 1.00 HMGCR (0.73) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL10540678 0.95 HMGCR (0.81) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL10779896 0.95 HMGCR (0.81) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL10540677 0.95 HMGCR (0.81) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL9626031 0.95 HMGCR (0.81) HMGCRPTPN7TDP1RECQLFFAR4
SCHEMBL10779903 0.95 HMGCR (0.81) HMGCRPTPN7TDP1RECQLFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038259-A1 Hydroxyeicosenoic acid anaglogs TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-02-17 US claimed
EP-1425258-A4 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 EP claimed
EP-1425258-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD (JP) 2004-06-09 EP claimed
WO-2003024390-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 WO claimed
US-20050038259-A1 Hydroxyeicosenoic acid anaglogs TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-02-17 US disclosed
EP-1425258-A4 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 EP disclosed
EP-1425258-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD (JP) 2004-06-09 EP disclosed
WO-2003024390-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038259-A1 Hydroxyeicosenoic acid anaglogs HCAR1, HRH4, HCAR3 HMGCR 226/4885PTPN7 2459/4885TDP1 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.